# Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

> **NCT00533923** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- AML
- ALL
- CLL
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Multiple Myeloma
- Aplastic Anemia
- Myeloproliferative Disorder

## Interventions

- **DRUG:** Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF

## Key facts

- **NCT ID:** NCT00533923
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2016-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533923, "Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00533923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*